Use of tricyclic antidepressants and risk of glioma: a nationwide case-control study.
BACKGROUND
A protective effect of tricyclic antidepressants (TCAs) against gliomas has been suggested by a small number of studies. We investigated this putative association in a nationwide setting.


METHODS
Using a case-control design, we identified all patients with histologically verified glioma (cases) in Denmark between 2000 and 2012 and matched these 1 : 20 to population controls. Conditional logistic regression was used to estimate adjusted odds ratios (ORs) for glioma associated with long-term (⩾3 years) use of TCAs. Similar analyses were performed for selective serotonin reuptake inhibitors (SSRIs).


RESULTS
We identified 3767 glioma cases and 75 340 population controls. Long-term use of TCAs was inversely associated with risk of glioma (OR 0.72, 95% CI: 0.41-1.25). Long-term SSRI use was not associated with glioma risk (OR 0.93, 95% CI: 0.75-1.16).


CONCLUSIONS
Our study indicated that long-term use of TCAs may be associated with a reduced risk of glioma, however, the statistical precision was limited. A similar pattern was not observed for use of SSRIs.
Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Anton
A
Pottegård
Centro Español Investigatión Farmacoepidemiológica (CEIFE), Madrid, Spain.
Luis Alberto
LA
García Rodríguez
Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Lotte
L
Rasmussen
Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.|Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
Per
P
Damkier
Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
Søren
S
Friis
Department of Neurology, Odense University Hospital, Odense, Denmark.|Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
David
D
Gaist
D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D016022:Case-Control Studies; D018890:Chemoprevention; D003718:Denmark / Q000453:epidemiology; D004363:Drug Utilization; D005260:Female; D005910:Glioma / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012306:Risk; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D055815:Young Adult
D016588:Anticarcinogenic Agents; D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors